Journal of Urologic Oncology

Editorial

July 31, 2024

Summarizing the Intentions and Outcomes of Journal of Urologic Oncology 2024 Issue 2

Cheol Kwak

J Urol Oncol. 2024;22(2):97-99.

Invited Review

July 31, 2024

A Narrative Review on Systemic Therapy for Renal Cell Carcinoma in the Perioperative Setting

Isamu Tachibana, Qian Qin, Jacob Taylor, et al.

J Urol Oncol. 2024;22(2):100-104.

In patients with renal cell carcinoma (RCC), the use of immunotherapy (IO) and tyrosine kinase inhibitor (TKI) regimens has proven beneficial in treating metastatic disease. These advances have led to...

Invited Review

July 31, 2024

Robot-Assisted Radical Nephrectomy With Inferior Vena Cava Thrombectomy: A Narrative Review With Step-by-Step Procedures

Seokhwan Bang, Sung-Hoo Hong

J Urol Oncol. 2024;22(2):105-114.

Inferior vena cava (IVC) thrombi are detected in 4%–10% of patients with renal cell carcinoma (RCC). The 5-year survival rates following radical nephrectomy (RN) with IVC thrombectomy for patients with...

Invited Review

July 31, 2024

Pathologic Diagnosis of Renal Cell Carcinoma in the Era of the 2022 World Health Organization Classification: Key Points for Clinicians

Bokyung Ahn, Jinahn Jeong, Yong Il Lee, et al.

J Urol Oncol. 2024;22(2):115-127.

The remarkable advances in our understanding of renal tumor pathogenesis, driven by the widespread application of molecular testing, are reflected in the latest 2022 World Health Organization classification. This updated...

Original Article

July 31, 2024

Diagnostic Accuracy of Contrast-Enhanced Ultrasonography for the Assessment of Small Renal Mass: A Prospective Study

Jae-Wook Chung, Seo Young Park, Seunghee Woo, et al.

J Urol Oncol. 2024;22(2):128-135.

Purpose: We prospectively compared the diagnostic accuracy of kidney dynamic computed tomography (KDCT), magnetic resonance imaging (MRI), and contrast-enhanced ultrasonography (CEUS) for the assessment of small renal mass (SRM) (≤4...

Original Article

July 31, 2024

Comparison of Outcomes Between Radical Nephrectomy and Partial Nephrectomy in Clinical T2 Renal Cell Carcinoma: A Retrospective Korean Renal Cell Carcinoma Cohort Study

Younsoo Chung, Seok-Soo Byun, Sung Kyu Hong, et al.

J Urol Oncol. 2024;22(2):136-143.

Purpose: We compared the surgical outcomes of radical nephrectomy (RN) and partial nephrectomy (PN) in adult patients with clinical T2 stage (cT2) renal cell carcinoma (RCC) by utilizing data from...

Invited Review

July 31, 2024

Health Equity Research Outcomes and Improvement Consortium Prostate Cancer Health Precision Africa1K: Closing the Health Equity Gap Through Rural Community Inclusion

Vanessa M. Hayes, Sean M. Patrick, Joyce Shirinde, et al.

J Urol Oncol. 2024;22(2):144-149.

Prostate cancer shows significant racial disparity, with men of African ancestry disproportionately impacted. While prostate cancer health disparity studies focus on elucidating the contributing socioeconomic, lifestyle, environmental, biological and underlying...

Review Article

July 31, 2024

The Integral Role and Clinical Significance of Metabolic Profiling in Prostate Cancer: A Narrative Review

Valentin Nikolaevich Pavlov, Marat Fayazovich Urmantsev, Marat Radikovich Bakeev, et al.

J Urol Oncol. 2024;22(2):150-156.

Prostate cancer (PC) is the most commonly diagnosed malignancy among males worldwide. In recent years, there has been a need to find alternative methods for the early diagnosis of PC....

Original Article

July 31, 2024

Changes in Treatment After Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography in Patients With Prostate Cancer: A Retrospective Case Series Study

Si Hyun Kim, Chang Wook Jeong, Minh-Tung Do, et al.

J Urol Oncol. 2024;22(2):157-165.

Purpose: The use of gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography (Ga-68 PSMA-11 PET/CT) is becoming increasingly common among men with prostate cancer (PCa). However, it remains uncertain which...

Invited Review

July 31, 2024

The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer

Ho Kyung Seo, Eui Hyun Jung, Sora Yang, et al.

J Urol Oncol. 2024;22(2):166-177.

Dysregulation of fibroblast growth factor (FGF)-receptor (FGFR) signaling, which is implicated in various oncogenic processes, including tumor proliferation, survival, migration, invasion, and angiogenesis, has been identified as a critical factor...

Original Article

July 31, 2024

Effects of Neoadjuvant Chemotherapy on Rates of Depression in Muscle Invasive Bladder Cancer

Matthew DeSanto, Frank H. Annie, Stacie Deslich, et al.

J Urol Oncol. 2024;22(2):178-182.

Purpose: The objective of this large retrospective cohort study is to better understand the relationship of bladder cancer and depression incidence, specifically relating to the incorporation of neoadjuvant chemotherapy (NCT)...

Erratum: Correction of Funding Information

July 31, 2024

Erratum: Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy

Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, et al.

J Urol Oncol. 2024;22(2):183-183.

Current Issue: Volume 22(2); Jul 2024

This archive contains links to the full-text of all issues.

Current issue

Volume 22(2); July

All issues

Vol. 22
2024

v.22(1) Mar 2024

v.22(2) Jul 2024

Vol. 21
2023

v.21(1) Mar 2023

v.21(2) Jul 2023

v.21(3) Nov 2023

The Korean Journal of Urological Oncology2003 (v1 n1) to 2022 (v22 n4)

Vol. 20
2022

v.20(1) Feb 2022

v.20(2) May 2022

v.20(3) Aug 2022

v.20(4) Nov 2022

Vol. 19
2021

v.19(1) Feb 2021

v.19(2) May 2021

v.19(3) Aug 2021

v.19(4) Nov 2021

Vol. 18
2020

v.18(1) Apr 2020

v.18(2) Aug 2020

v.18(3) Dec 2020

Vol. 17
2019

v.17(1) Apr 2019

v.17(2) Aug 2019

v.17(3) Dec 2019

Vol. 16
2018

v.16(1) Apr 2018

v.16(2) Aug 2018

v.16(3) Dec 2018

Vol. 15
2017

v.15(1) Apr 2017

v.15(2) Aug 2017

v.15(3) Dec 2017

Vol. 14
2016

v.14(1) Apr 2016

v.14(2) Aug 2016

v.14(3) Dec 2016

Vol. 13
2015

v.13(1) Apr 2015

v.13(2) Aug 2015

v.13(3) Dec 2015

Vol. 12
2014

v.12(1) Apr 2014

v.12(2) Aug 2014

v.12(3) Dec 2014

Vol. 11
2013

v.11(1) Apr 2013

v.11(2) Aug 2013

v.11(3) Dec 2013

Vol. 10
2012

v.10(1) Apr 2012

v.10(2) Aug 2012

v.10(3) Dec 2012

Vol. 9
2011

v.9(1) Apr 2011

v.9(2) Aug 2011

v.9(3) Dec 2011

Vol. 8
2010

v.8(1) Apr 2010

v.8(2) Aug 2010

v.8(3) Dec 2010

Vol. 7
2009

v.7(1) Apr 2009

v.7(2) Aug 2009

v.7(3) Dec 2009

Vol. 6
2008

v.6(1) Apr 2008

v.6(2) Aug 2008

v.6(3) Dec 2008

Vol. 5
2007

v.5(1) Apr 2007

v.5(2) Aug 2007

v.5(3) Dec 2007

Vol. 4
2006

v.4(1) Jun 2006

v.4(2) Dec 2006

Vol. 3
2005

v.3(1) Jun 2005

v.3(2) Dec 2005

Vol. 2
2004

v.2(1) Mar 2004

v.2(2) Jun 2004

v.2(3) Sep 2004

v.2(4) Dec 2004

Vol. 1
2003

v.1(1) Mar 2003

v.1(2) Jun 2003

v.1(3) Sep 2003

v.1(4) Dec 2003

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043

5,263	New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer
4,829	The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
4,202	The Present and Future of Intravesical Therapy in Bladder Cancer
3,980	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
3,929	Complex Epidemiology of Prostate Cancer in Asian Countries

Cited By 6	Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Cited By 4	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
Cited By 3	The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials
Cited By 2	Complex Epidemiology of Prostate Cancer in Asian Countries
Cited By 2	Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use